Novo Nordisk leads Eli Lilly in weight-loss pills
Novo Nordisk's Wegovy pill is capturing the majority of the early GLP-1 oral market share over Eli Lilly's competing offering.
The argument
The discussion noted that Novo Nordisk's pill is pulling ahead of Eli Lilly's, with Lilly capturing only about 11% of the prescription volume for new pills. Doctors attribute this preference to studies showing greater average weight loss with Novo's Wegovy pill compared to Lilly's Foundeo.
The thesis, stress-tested
✓ What validates it
- ✓Quarterly prescription volume data showing Novo Nordisk maintaining or expanding its market share lead
- ✓Clinical trial data releases comparing the efficacy of next-generation oral formulations
▸ Risks discussed
- ▸Production capacity constraints for oral GLP-1 formulations
- ▸Potential side effects or long-term safety concerns emerging from broader clinical use
Hear it yourself
"While Lilly is the market leader in obesity shots, it hasn't yet made a major dent in the pill market, capturing only about 11% of prescription volume for new pills. Doctors say patients prefer Novo's Wegovy pill over Lilly's FOUNDEO because studies show it leads to greater average weight loss."
00:00 / 00:19
AFFILIATE LINK · ZORTIX MAY EARN A COMMISSION · NEVER A RECOMMENDATION TO TRADE